The biggest and most comprehensive analysis of GLP-1 receptor agonists on kidney and cardiovascular outcomes shows that they significantly benefit people with and without diabetes.
Study finds popular diabetes and obesity drugs also protect kidneys
November 27, 2024 Latest NewsBioPharmaLatest Video
New Stories
-
Novartis partners with Advara HeartCare and TerryWhite Chemmart to launch Heart Health Collective,
December 6, 2024 - - Latest News -
Pfizer Australia launches Innovate Reconciliation Action Plan to advance equitable access to health and wellbeing
December 6, 2024 - - BioPharma -
Former CSL CEO Paul Perreault appointed strategic adviser to Microbio
December 5, 2024 - - Latest News -
More evidence backs the use of weight-loss therapies
December 5, 2024 - - Latest News -
ChatGPT would have produced more human responses than these committees
December 5, 2024 - - Latest News -
Anatara provides irritable bowel syndrome clinical trial update
December 4, 2024 - - Australian Biotech -
Digital health company Adherium secures R&D loan facility
December 4, 2024 - - Australian Biotech